CLINICAL_TRIALS ClinicalTrials.gov record update

Phase 2 Multi-center Randomized Study to the Efficacy and Safety of AK105 Combined With Anrotinib Hydrochloride in Patients With Recurrent/Refractory Classical Hodgkin's Lymphoma

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Record identity and dates

Source: ClinicalTrials.gov
Source record ID: NCT05683704
Title field or adapter rule: protocolSection.identificationModule.officialTitle
Ingested At: 2026-04-28T10:38:50.723036+00:00
Published At: 2023-01-13T00:00:00+00:00
Record Updated At: 2023-01-13
Timestamp Basis: source retrieval time was not retained by the feed adapter
Date limitation: source retrieval time was not retained by the feed adapter

protocolSection.conditionsModule.conditions: ["Recurrent/Refractory Classical Hodgkin\u0027s Lymphoma"]
protocolSection.statusModule.lastUpdatePostDateStruct.date: "2023-01-13"
protocolSection.identificationModule.nctId: "NCT05683704"
protocolSection.identificationModule.officialTitle: "Phase 2 Multi-center Randomized Study to the Efficacy and Safety of AK105 Combined With Anrotinib Hydrochloride in Patients With Recurrent/Refractory Classical Hodgkin\u0027s Lymphoma"
protocolSection.statusModule.overallStatus: "ENROLLING_BY_INVITATION"
protocolSection.designModule.phases: ["PHASE2"]
protocolSection.statusModule.resultsFirstPostDateStruct.date: ""

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.